Edesa Biotech, Inc. (EDSA)
NASDAQ: EDSA · Real-Time Price · USD
5.55
+0.32 (6.12%)
At close: Apr 1, 2026, 4:00 PM EDT
5.40
-0.15 (-2.70%)
After-hours: Apr 1, 2026, 4:33 PM EDT
Edesa Biotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
46.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | - | - | - |
| Sep 30, 2024 | - | - | - |
| Sep 30, 2023 | - | - | - |
| Sep 30, 2022 | - | - | - |
| Sep 30, 2021 | - | - | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immutep | 5.28M |
| Nutriband | 2.28M |
| Aligos Therapeutics | 2.19M |
| Werewolf Therapeutics | 1.14M |
| RenovoRx | 1.12M |
| Rallybio | 858.00K |
| Lisata Therapeutics | 170.00K |
EDSA News
- 1 day ago - Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit - GlobeNewsWire
- 6 days ago - Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment - GlobeNewsWire
- 5 weeks ago - Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study - GlobeNewsWire
- 6 weeks ago - Edesa Biotech Reports Fiscal 1st Quarter 2026 Results - GlobeNewsWire
- 3 months ago - Edesa Biotech Reports Fiscal Year 2025 Results - GlobeNewsWire
- 5 months ago - Edesa Biotech Announces Upcoming Conference Schedule - GlobeNewsWire
- 5 months ago - Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study - GlobeNewsWire
- 8 months ago - Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results - GlobeNewsWire